It's Tuesday, November 17th, I'm Heila Hughes.

And I'm Gideon Resneck and this is what a day where we were finally getting over not being featured on Obama's playlist.

Like, I definitely think that we could have been featured right between Sir Duke by Stevie Wonder and lose yourself by him and him, but fine.

Those are the energies that we bring, I think. You know, it's right in the middle pocket there.

On Zayshow, what's to know about the candidates running in Georgia's runoff, then some headlines.

But first the latest.

You spoke about the need to access the outgoing administration's COVID vaccine distribution plans.

What do you see as the biggest threat to your transition right now, given President Trump's unprecedented attempt to obstruct and delay a smooth transfer of power?

More people may die. If we don't coordinate look.

As my chief of staff Ron claim would say who handled Ebola.

A vaccine is important. It's a little illusion to your vaccinated.

So how do we get the vaccine? How do we get over 300 million Americans vaccinated?

That was President elect Joe Biden talking about the challenges involved in vaccine distribution as well as the Trump administration's lack of cooperation with his transition team at the moment.

The upcoming months are likely to be devastating in terms of the pandemic, but there was another piece of very good news yesterday on vaccine development.

That is right. So Moderna announced yesterday that an initial analysis of its vaccine found it was 94.5% effective, which is amazing.

This comes a week after Pfizer's initial announcement of their own vaccine.

Moderna said that in its trials, which involved giving people the vaccine and others a saltwater placebo 95 participants had contracted COVID-19 with five of them being people who were vaccinated and the other 90 being those who got that placebo.

They also said that there were 11 severe cases, which were all in the placebo group.

Now it's a good sign if none of the vaccinated people got severe COVID here.

Overall, they had 30,000 people enrolled by the end of October and according to the New York Times, they ended up with 37% enrollment from communities of color and 42% from high-risk populations that's due to age or other health factors.

And as was the case with Pfizer, the fact that the pandemic is so fundamentally out of control in the United States seemed to speed their trial process along.

Moderna has said that they want to complete the trial before applying for authorization from the FDA.

...